Drug Profile
Research programme: neurodegeneration and cancer therapeutics - AbbVie/Calico
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator AbbVie; Calico
- Developer Calico
- Class Antineoplastics; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Neurodegenerative disorders
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2018 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2018 No recent reports of development identified for research development in Neurodegenerative-disorders in USA